WO1994021241A1 - New use of anti-acne agents - Google Patents

New use of anti-acne agents Download PDF

Info

Publication number
WO1994021241A1
WO1994021241A1 PCT/EP1994/000769 EP9400769W WO9421241A1 WO 1994021241 A1 WO1994021241 A1 WO 1994021241A1 EP 9400769 W EP9400769 W EP 9400769W WO 9421241 A1 WO9421241 A1 WO 9421241A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparations
acid
weight
acne
cosmetic
Prior art date
Application number
PCT/EP1994/000769
Other languages
German (de)
French (fr)
Inventor
Gerhard Sauermann
Franz STÄB
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Priority to JP6520613A priority Critical patent/JPH08507772A/en
Priority to EP94911877A priority patent/EP0689431A1/en
Publication of WO1994021241A1 publication Critical patent/WO1994021241A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38—Percompounds, e.g. peracids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Definitions

  • the present invention relates to active ingredients and preparations which serve for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses.
  • UVC range rays with a wavelength shorter than 290 nm
  • UVB range rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema simple sunburn or even more or less severe burns.
  • the narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
  • Numerous compounds are known for protection against UVB radiation, which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also 2-phenylbenzimidazole.
  • UVA range It is also important for the range between about 320 nm and about 400 nm, the so-called UVA range, To have filter substances available because their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation damages elastic and collagen fibers. it carries connective tissue, which causes the skin to age prematurely, and that it can be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products intervene in the skin metabolism.
  • Such photochemical reaction products are predominantly free radical compounds, for example hydroxy radicals.
  • Undefined radical photo products which arise in the skin itself can also display uncontrolled subsequent reactions due to their high reactivity.
  • singlet oxygen a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others.
  • Singlet oxygen for example, is characterized by increased reactivity compared to the triplet oxygen that is normally present (basic radical state).
  • UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV rays, which in turn can oxidatively intervene in the biochemical processes.
  • antioxidants and / or free radical scavengers can be incorporated into the cosmetic or dermatological formulations.
  • vitamin E a substance with a known antioxidative effect, in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • the object of the invention is to provide cosmetic, dermatological and pharmaceutical active substances and preparations as well as light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses, preferably PLD.
  • the invention also relates to the mixtures of the active substances and preparations therewith. Preparations according to the invention which contain a UV protective agent are particularly preferred.
  • Acne agents or acne active ingredients are known in large numbers. It can be cosmetic, dermatological and pharmaceutical active ingredients which e.g. can be administered orally, parenterally or topically. Their effect according to the invention is surprising since there are no indications of an effect in photodermatoses. The term “Mallorca acne” is misleading in this context, since this so-called “acne” is not one of the acne forms.
  • Preferred acne active ingredients are vitamin A and derivatives, antibiotics from the acne treatment spectrum such as clindamycin and tratracyclines, but especially those which have antibacterial activity against propionibacteria, keratolytics such as salicylic acid and alpha-hydroxy acids and preparations, in particular topical preparations with them .
  • Benzoyl peroxide and in particular also topical preparations are particularly preferred.
  • Benzoyl peroxide and preparations with it, together with an antibacterial agent are preferred. in particular an antibacterial acne agent used.
  • the acne agents are used in the same way as in the acne treatment and in the preparations known in the process.
  • agents against acne or propionibacteria or comedones are particularly preferred:
  • Vitamin A acid (all-trans retinoic acid) e.g. in
  • Benzoyl peroxide e.g. in topical preparations such as emulsions, gels, creams, preferably with 0.5 to 20 wt .-%, in particular 2.5 to 10 wt .- /. salary
  • topical antibiotics such as
  • Salicylic acid e.g. in topical preparations with 1 to 10% by weight
  • Azelaic acid for example in creams with 1 to 20% by weight, preferably 15 20 6% by weight of active substance, oral antibiotics such as
  • Tretracyclines, macrolides e.g. Doxycycline, minocycline, erythromycin, josamycin, e.g. with daily doses of 50 to 1500 mg
  • Isotretinoin e.g. with daily doses of 2.5 to 40 mg
  • Vitamin A retinol
  • Retinol palmitate applied topically, e.g. in solutions,
  • Cyproterone acetate e.g. with daily doses of 5 to 100 mg.
  • the acne agents used according to the invention preferably also contain antioxidants.
  • Preferred antioxidants are thiols, e.g. Cysteine and cysteine derivatives, glutathione, cystine, N-acetylcysteine, lipoic acid, folic acid, ubiquinone, phytic acid, alpha-hydroxy acids such as e.g. Citric acid and lactic acid, zinc sulfate, zinc oxide, vitamin C, vitamin E, carotene.
  • thiols e.g. Cysteine and cysteine derivatives, glutathione, cystine, N-acetylcysteine, lipoic acid, folic acid, ubiquinone, phytic acid, alpha-hydroxy acids such as e.g. Citric acid and lactic acid, zinc sulfate, zinc oxide, vitamin C, vitamin E, carotene.
  • the cosmetic or dermatological preparations according to the invention contain antioxidants, for example in amounts of 0.01% by weight to 10% by weight, preferably in amounts of 0.5% by weight to 6% by weight, but in particular 2 % By weight to 4% by weight based on the total weight of the preparations.
  • the active substances according to the invention and the preparations obtained therewith have a prophylactic effect in that they protect the light-sensitive skin and prevent or reduce the formation of PLD. For this purpose, they are used before sun exposure.
  • Photodermatoses and manifest PLE take place in the treatment with the active substances and preparations according to the invention, an improvement in the skin conditions and a faster decay, e.g. the PLD or the photodermatosis.
  • Cosmetic and dermatological preparations which are in the form of a sunscreen are particularly preferred. These preferably additionally contain at least one UVA filter and / or at least one further UVB filter and / or at least one inorganic pigment.
  • Cosmetic and dermatological preparations according to the invention for protecting the skin from UV rays can be in various forms, such as those e.g. are usually used for this type of preparation. So you can e.g. a solution, an emulsion of the type water-in-oil (W / 0) or of the type oil-in-water (0 / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W), a gel, a solid stick or an aerosol.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries of the kind normally used in such preparations, for example preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, Thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries of the kind normally used in such preparations, for example preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, Thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols
  • the cosmetic or dermatological preparation is a solution or lotion, ⁇ .B. used as solvents:
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
  • ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol onomethyl or monoethyl ether and analog products.
  • Emulsions according to the invention for example in the form of a sunscreen cream or sunscreen milk, are preferred and contain, for example, the fats, oils, waxes and other fat bodies mentioned, as well as water and an emulsifier, as is customarily used for such a type of formulation.
  • Gels according to the invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickener, which is preferred in the case of oily-alcoholic gels, preferably silicon dioxide or an aluminum silicate, in the case of aqueous-alcoholic or alcoholic gels is a polyacrylate.
  • low C number alcohols e.g. Ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickener, which is preferred in the case of oily-alcoholic gels, preferably silicon dioxide or an aluminum silicate, in the case of aqueous-alcoholic or alcoholic gels is a polyacrylate.
  • Fixed pins according to the invention contain e.g. natural or synthetic waxes, fatty alcohols or fatty acid esters. Lip care sticks are preferred.
  • Suitable blowing agents for cosmetic deodorants according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied blowing agents, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • the topical preparations according to the invention can preferably also contain substances which absorb UV radiation in the UVA and / or in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10 wt. , in particular 1 to 6% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
  • the UVB filters can be oil-soluble or water-soluble.
  • oil-soluble substances e.g. to call:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycytic acid isopentyl ester;
  • esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester;
  • UVB filters should, of course, not be limiting.
  • the invention also relates to preparations according to the invention with combinations of a UVA filter with a UVB filter or cosmetic or dermatological preparations according to the invention which also contain a UVB filter.
  • UVA filters which have hitherto usually been contained in cosmetic preparations.
  • These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'- tert-Butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- (4 '-isopropylphenyl) propane-1, 3-dione.
  • Cosmetic and dermatological preparations according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide. These combinations of UVA filter and pigment or preparations containing this combination are also the subject of the invention. The amounts given for the above combinations can be used.
  • the invention also relates to the process for the production of the cosmetic compositions according to the invention, which is characterized in that the active ingredients according to the invention are incorporated into cosmetic and dermatological formulations in a manner known per se.
  • the preparations are prepared in a manner known per se, in particular by mixing the constituents, if appropriate at elevated temperature. Fat and water phase are produced separately and mixed or emulsified if necessary at elevated temperature.
  • a mixture of 6.3% by weight of wool wax alcohols and 6.5% by weight of paraffin oil is added to the fat phase at 75 ° C.
  • the fat phase is then added to the 75 ° C warm water phase, stirred and homogenized until a uniform white cream has formed.
  • Example I has the following final composition:
  • Fat phase wt. . -%
  • the fat phase at 75 ° C. is added to the water phase at 75 ° C., stirred and homogenized until a uniform white cream has formed.
  • game III
  • a hydrogel is produced in the usual way with the constituents mentioned.
  • Carbomer 5984 (B.F. Goodrich) 0.25%
  • a gel is produced with the ingredients in the usual way.

Abstract

Active agents or preparations that are used or suited for treating acne can be used for prophylaxis or treatment of light-sensitive skin, in particular photodermatoses, and preferably polymorphous photodermatosis.

Description

Beschreibung description
Neue Verwendung von A nemittelnNew use of drugs
Die vorliegende Erfindung betrifft Wirkstoffe und Zuberei¬ tungen, die zur Prophylaxe und Behandlung der lichtem¬ pfindlichen Haut, insbesondere von Photoder atosen , die¬ nen .The present invention relates to active ingredients and preparations which serve for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses.
Die schädigende Wirkung des ultravioletten Teils der Son¬ nenstrahlung auf die Haut ist allgemein bekannt. Während Strahlen mit einer Wellenlänge, die kleiner als 290 nm ist (der sogenannte UVC-Bereich) , von der Ozonschicht in der Erdatmosphäre absorbiert werden, verursachen Strahlen im Bereich zwischen 290 nm und 320 nm, dem sogenannten UVB-Bereich, ein Erythem, einen einfachen Sonnenbrand oder sogar mehr oder weniger starke Verbrennungen.The damaging effect of the ultraviolet part of the sun's radiation on the skin is generally known. While rays with a wavelength shorter than 290 nm (the so-called UVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema simple sunburn or even more or less severe burns.
Als ein Maximum der Erythemwirksamkeit des Sonnenlichtes wird der engere Bereich um 308 nm angegeben.The narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
Zum Schutz gegen UVB-Strahlung sind zahlreiche Verbindun¬ gen bekannt, bei denen es sich um Derivate des 3-Benzyl- idencamphers , der 4-Aminobenzoesäure, der Zimtsäure, der Salicylsäure, des Benzophenons sowie auch des 2-Phenyl- benzimidazols handelt.Numerous compounds are known for protection against UVB radiation, which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also 2-phenylbenzimidazole.
Auch für den Bereich zwischen etwa 320 nm und etwa 400 nm, des sogenannten UVA-Bereich, ist es wichtig, Filtersubstanzen zur Verfügung zu haben, da dessen Strahlen Reaktionen bei lichtempfindlicher Haut hervorrufen können. Es ist erwiesen, daß UVA-Strahlung zu einer Schädigung der elastischen und kollagenen Fasern. es Bindegewebes führt, was die Haut vorzeitig altern läßt, und daß sie als Ursache zahlreicher phototoxischer und photoallergischer Reaktionen zu sehen ist. Der schädigende Einfluß der UVB-Strahlung kann durch UVA-Strahlung verstärkt werden.It is also important for the range between about 320 nm and about 400 nm, the so-called UVA range, To have filter substances available because their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation damages elastic and collagen fibers. it carries connective tissue, which causes the skin to age prematurely, and that it can be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
Zum Schutz gegen die Strahlen des UVA-Bereichs werden da¬ her gewisse Derivate des Dibenzoylmethans verwendet, deren Photostabilität (Int. J. Cosm. Science j_0, 53 (1988)), nicht in ausreichendem Maße gegeben ist.To protect against the rays of the UVA range, certain derivatives of dibenzoylmethane are therefore used, the photostability (Int. J. Cosm. Science j_0, 53 (1988)) of which is insufficient.
Die UV-Strahlung kann aber auch zu photochemischen Reakti¬ onen führen, wobei dann die photochemischen Reaktionspro¬ dukte in den Hautmetabolismus eingreifen.However, UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products intervene in the skin metabolism.
Vorwiegend handelt es sich bei solchen photochemischen Reaktionsprodukten um radikalische Verbindungen, bei¬ spielsweise Hydroxyradikale. Auch Undefinierte radikali¬ sche Photoprodukte, welche in der Haut selbst entstehen, können aufgrund ihrer hohen Reaktivität unkontrollierte Folgereaktionen an den Tag legen. Aber auch Singulett- sauerstoff, ein nichtradikalischer angeregter Zustand des Sauerstoffmoleküls kann bei UV-Bestrahlung auftreten, ebenso kurzlebige Epoxide und viele andere. Singulett- sauerstoff beispielsweise zeichnet sich gegenüber dem normalerweise vorliegenden Triplettsauerstoff (radikali¬ scher Grundzustand) durch gesteigerte Reaktivität aus. Allerdings existieren auch angeregte, reaktive ( radikal i- sche) Triplettzustände des Sauerstoffmoleküls . Ferner zählt UV-Strahlung zur ionisierenden Strahlung. Es besteht also das Risiko, daß auch ionische Spezies bei UV-Exposition entstehen, welche dann ihrerseits oxidativ in die biochemischen Prozesse einzugreifen vermögen.Such photochemical reaction products are predominantly free radical compounds, for example hydroxy radicals. Undefined radical photo products which arise in the skin itself can also display uncontrolled subsequent reactions due to their high reactivity. But also singlet oxygen, a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others. Singlet oxygen, for example, is characterized by increased reactivity compared to the triplet oxygen that is normally present (basic radical state). However, there are also excited, reactive (radical) triplet states of the oxygen molecule. UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV rays, which in turn can oxidatively intervene in the biochemical processes.
Um diesen Reaktionen vorzubeugen, können den kosmetischen bzw. dermatologischen Formulierungen zusätzliche Anti- oxidantien und/oder Radikalfänger einverleibt werden.In order to prevent these reactions, additional antioxidants and / or free radical scavengers can be incorporated into the cosmetic or dermatological formulations.
Es ist bereits vorgeschlagen worden, Vitamin E, eine Sub¬ stanz mit bekannter antioxidativer Wirkung in Lichtschutz¬ formulierungen einzusetzen, dennoch bleibt auch hier die erzielte Wirkung weit hinter der erhofften zurück.It has already been proposed to use vitamin E, a substance with a known antioxidative effect, in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
Aufgabe der Erfindung ist es, kosmetische, dermatologische und pharmazeutische Wirkstoffe und Zubereitungen sowie Lichtschutzformulierungen zu schaffen, die zur Prophylaxe und Behandlung lichtempfindlicher Haut, insbesondere Photodermatosen, bevorzugt PLD dienen.The object of the invention is to provide cosmetic, dermatological and pharmaceutical active substances and preparations as well as light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses, preferably PLD.
Diese Aufgabe wird gelöst durch die Verwendung von Wirk¬ stoffen oder Zubereitungen, die zur Aknebehandlung dienen oder geeignet sind, zur Prophylaxe und Behandlung von lichtempfindlicher Haut, insbesondere Photodermatosen und bevorzugt der polymorphen Lichtdermatose.This object is achieved by the use of active substances or preparations which serve or are suitable for acne treatment, for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses and preferably polymorphic light dermatosis.
Weitere Bezeichnungen für die poly orphe Lichtdermatose sind PLD, PLE, Mallorca-Akne und eine Vielzahl von wei¬ teren Bezeichnungen, wie sie in der Literatur (z.B. A. Voelckel et al, Zentralblatt Haut- und Geschlechtskrank¬ heiten (1989), 156, Seite 2), angegeben sind.Further names for polyorpheic light dermatosis are PLD, PLE, Mallorca acne and a large number of other names, such as those used in the literature (e.g. A. Voelckel et al, Zentralblatt Haut- und Sexterlechtenungen (1989), 156, Page 2).
Gegenstand der Erfindung sind auch die Gemische der Wirk¬ stoffe und Zubereitungen damit. Erfindungsgemäße Zubereitungen, die ein UV-Schutzmittel enthalten, werden besonders bevorzugt.The invention also relates to the mixtures of the active substances and preparations therewith. Preparations according to the invention which contain a UV protective agent are particularly preferred.
Aknemittel oder gegen Akne wirkende Wirkstoffe sind in. großer Zahl bekannt. Es können kosmetische, dermatologi¬ sche und pharmazeutische Wirkstoffe sein, die z.B. oral, parenteral oder topisch verabreicht werden können. Ihre erfindungsgemäße Wirkung ist überraschend, da Hinweise auf eine Wirkung bei Photodermatosen nicht vorliegen. Der Be¬ griff "Mallorca-Akne" ist in diesem Zusammenhang irrefüh¬ rend, da diese sogenannte "Akne" nicht zu den Akneformen gehört.Acne agents or acne active ingredients are known in large numbers. It can be cosmetic, dermatological and pharmaceutical active ingredients which e.g. can be administered orally, parenterally or topically. Their effect according to the invention is surprising since there are no indications of an effect in photodermatoses. The term "Mallorca acne" is misleading in this context, since this so-called "acne" is not one of the acne forms.
Ferner war überraschend, daß die erfindungsgemäßen Wirk¬ stoffe bei in der menschlichen Haut relevanten photoche¬ mischen Oxidationsprozessen wirksam sein würden.It was also surprising that the active substances according to the invention would be effective in photochemical oxidation processes relevant in human skin.
Die Ursache der neuen erfindungsgemäßen Wirkung von Akne- mitteln ist noch nicht vollständig geklärt. Es könnte aber möglicherweise ein Zusammenhang mit der Porphyrinbildung durch Propionibakterien bestehen, die in den menschlichen Talgdrüsen vorkommen, und auch mit der Spaltung von Porphyrinen durch Enzyme.The cause of the new acne remedies according to the invention has not yet been completely clarified. However, there may be a connection with the formation of porphyrin by propionibacteria, which are found in the human sebaceous glands, and also with the cleavage of porphyrins by enzymes.
Bevorzugte Aknewirkstoffe sind Vitamin A und Derivate, Antibiotika des Aknebehandlungsspektrums wie Clindamycin und Tratracycline, insbesondere aber solche, die antibak¬ terielle Wirkung gegen Propionibakterien aufweisen, wei¬ terhin Keratolytika wie Salicylsäure und alpha-Hydroxy- säuren und Zubereitungen, insbesondere topische Zuberei¬ tungen damit. Besonders bevorzugt werden Benzoylperoxid und insbesondere auch topische Zubereitungen damit.Preferred acne active ingredients are vitamin A and derivatives, antibiotics from the acne treatment spectrum such as clindamycin and tratracyclines, but especially those which have antibacterial activity against propionibacteria, keratolytics such as salicylic acid and alpha-hydroxy acids and preparations, in particular topical preparations with them . Benzoyl peroxide and in particular also topical preparations are particularly preferred.
Bevorzugt werden Benzoylperoxid und Zubereitungen damit, zusammen mit einem antibakteriell wirkendem Mittel, insbesondere einem antibakteriell wirkendem Aknemittel, verwendet.Benzoyl peroxide and preparations with it, together with an antibacterial agent, are preferred. in particular an antibacterial acne agent used.
Die Aknemittel werden, wenn sie erfindungsgemäß verwendet werden, in der gleichen Weise eingesetzt wie bei der Akne¬ behandlung und in den dabei bekannten Zubereitungen.When used according to the invention, the acne agents are used in the same way as in the acne treatment and in the preparations known in the process.
Folgende Mittel gegen Akne bzw. Propionibakterien bzw. Comedone werden besonders bevorzugt:The following agents against acne or propionibacteria or comedones are particularly preferred:
Vitamin A-Säure (all-trans Retinsäure), z.B. inVitamin A acid (all-trans retinoic acid) e.g. in
0,05 bis 0,025 Gew.- igen Lösungen, Cremes oder Gelen,0.05 to 0.025% by weight solutions, creams or gels,
Benzoylperoxid, z.B. in topischen Zubereitungen wie Emulsionen, Gelen, Cremes, mit vorzugsweise 0,5 bis 20 Gew.-%, insbesondere 2,5 bis 10 Gew.-/. GehaltBenzoyl peroxide, e.g. in topical preparations such as emulsions, gels, creams, preferably with 0.5 to 20 wt .-%, in particular 2.5 to 10 wt .- /. salary
topisch anzuwendende Antibiotika, wietopical antibiotics, such as
Tretracycline, Erythromycin, Clinda- mycin in Salben, Cremes, Gelen, Lösun¬ gen mit z.B. 1 bis 3 Gew.-% Wirkstoff¬ gehalt, gegebenenfalls in Kombination mit Benzoylperoxid, Tretinoin, Zink- acetat,Tretracyclines, erythromycin, clindamycin in ointments, creams, gels, solutions with e.g. 1 to 3% by weight of active ingredient, optionally in combination with benzoyl peroxide, tretinoin, zinc acetate,
Salicylsäure, z.B. in topischen Zubereitungen mit 1 bis 10 Gew.-% Gehalt,Salicylic acid, e.g. in topical preparations with 1 to 10% by weight,
Azelainsäure, z.B. in Cremes mit 1 bis 20 Gew. vorzugsweise 15 20 6ew.-% Wirk- Stoffgehalt, oral anzuwendende Antibiotica wieAzelaic acid, for example in creams with 1 to 20% by weight, preferably 15 20 6% by weight of active substance, oral antibiotics such as
Tretracycline, Macrolide, z.B. Doxy- cyclin, Minocyclin, Erythromycin , Josamycin, z.B. mit Tagesdosen von 50 bis 1500 mgTretracyclines, macrolides, e.g. Doxycycline, minocycline, erythromycin, josamycin, e.g. with daily doses of 50 to 1500 mg
Isotretinoin , z.B. mit Tagesdosen von 2,5 bis 40 mgIsotretinoin, e.g. with daily doses of 2.5 to 40 mg
Vitamin A (Retinol), oral verabreicht z.B. bisVitamin A (retinol), administered orally e.g. to
40 mg pro Tag40 mg a day
Retinolpalmitat , topisch angewendet, z.B. in Lösungen,Retinol palmitate, applied topically, e.g. in solutions,
Cremes, Gelen mit 0,1 bis 5 Gew.-!. WirkstoffgehaltCreams, gels with 0.1 to 5% by weight !. Active substance content
Cyproteron-Acetat, z.B. mit Tagesdosen von 5 bis 100 mg.Cyproterone acetate, e.g. with daily doses of 5 to 100 mg.
Vorzugsweise enthalten die erfindungsgemäß verwendeten Aknemittel auch Antioxydantien .The acne agents used according to the invention preferably also contain antioxidants.
Bevorzugte Antioxydantien sind Thiole, z.B. Cystein und Cystein-Derivate, Glutathion, Cystin, N-Acetylcystein , Liponsäure, Folsäure, Ubiquinon, Phytinsäure, alpha-Hydroxysäuren wie z.B. Zitronensäure und Milchsäure, Zinksulfat, Zinkoxid, Vitamin C, Vitamin E, Carotin.Preferred antioxidants are thiols, e.g. Cysteine and cysteine derivatives, glutathione, cystine, N-acetylcysteine, lipoic acid, folic acid, ubiquinone, phytic acid, alpha-hydroxy acids such as e.g. Citric acid and lactic acid, zinc sulfate, zinc oxide, vitamin C, vitamin E, carotene.
Die kosmetischen oder dermatologischen Zubereitungen gemäß der Erfindung enthalten Antioxidantien z.B. in Mengen von 0,01 Gew.-.ό bis 10 Gew.-%, vorzugsweise in Mengen von 0,5 Gew.-Λ bis 6 Gew.-%, insbesondere aber 2 Gew.-% bis 4 Gew.-?ό bezogen auf das Gesamtgewicht der Zubereitungen. Die erfindungsgemäßen Wirkstoffe und damit erhaltenen Zu¬ bereitungen sind prophylaktisch wirksam, indem sie die lichtempfindliche Haut schützen und die Ausbildung von PLD verhindern oder mildern. Dazu werden sie vor der Sonnenbe¬ strahlung angewandt.The cosmetic or dermatological preparations according to the invention contain antioxidants, for example in amounts of 0.01% by weight to 10% by weight, preferably in amounts of 0.5% by weight to 6% by weight, but in particular 2 % By weight to 4% by weight based on the total weight of the preparations. The active substances according to the invention and the preparations obtained therewith have a prophylactic effect in that they protect the light-sensitive skin and prevent or reduce the formation of PLD. For this purpose, they are used before sun exposure.
Bei z.B. Photodermatosen und manifester PLE erfolgt bei der Behandlung mit den erfindungsgemäßen Wirkstoffen und Zubereitungen eine Besserung der Hautzustände und ein schnelleres Abklingen z.B. der PLD oder der Photodermatosen.With e.g. Photodermatoses and manifest PLE take place in the treatment with the active substances and preparations according to the invention, an improvement in the skin conditions and a faster decay, e.g. the PLD or the photodermatosis.
Besonders bevorzugt sind solche kosmetischen und derma¬ tologischen Zubereitungen, die in der Form eines Sonnen¬ schutzmittels vorliegen. Vorzugsweise enthalten diese zusätzlich mindestens einen UVA-Filter und/oder mindestens einen weiteren UVB-Filter und/oder mindestens ein anorga¬ nisches Pigment.Cosmetic and dermatological preparations which are in the form of a sunscreen are particularly preferred. These preferably additionally contain at least one UVA filter and / or at least one further UVB filter and / or at least one inorganic pigment.
Erfindungsgemäße kosmetische und dermatologische Zuberei¬ tungen zum Schütze der Haut vor UV-Strahlen können in ver¬ schiedenen Formen vorliegen, wie sie z.B. üblicherweise für diesen Typ von Zubereitungen eingesetzt werden. So können sie z.B. eine Lösung, eine Emulsion vom Typ Wasser¬ in-Öl (W/0) oder vom Typ Öl-in-Wasser (0/W), oder eine multiple Emulsionen, beispielsweise vom Typ Wasser-in-öl- in-Wasser (W/O/W), ein Gel, einen festen Stift oder auch ein Aerosol darstellen.Cosmetic and dermatological preparations according to the invention for protecting the skin from UV rays can be in various forms, such as those e.g. are usually used for this type of preparation. So you can e.g. a solution, an emulsion of the type water-in-oil (W / 0) or of the type oil-in-water (0 / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W), a gel, a solid stick or an aerosol.
Die erfindungsgemäßen kosmetischen und dermatologischen Zubereitungen können kosmetische Hilfsstoffe enthalten, wie sie üblicherweise in solchen Zubereitungen verwendet werden, z.B. Konservierungsmittel, Bakterizide, Parfüme, Substanzen zum Verhindern des Schäumens, Farbstoffe, Pigmente, die eine färbende Wirkung haben, Verdickungsmittel , oberflächenaktive Substanzen, Emulgatoren, weichmachende, anfeuchtende und/oder feuchhaltende Substanzen, Fette, Öle, Wachse oder andere übliche Bestandteile einer kosmetischen oder dermatologischen Formulierung wie Alkohole, Polyole, Polymere, Schaumstabilisatoren, Elektrolyte, organische Lösungsmittel oder Silikonderivate.The cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries of the kind normally used in such preparations, for example preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, Thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Sofern die kosmetische oder dermatologische Zubereitung eine Lösung oder Lotion darstellt, können^.B. als Lösungsmittel, verwendet werden:If the cosmetic or dermatological preparation is a solution or lotion, ^ .B. used as solvents:
Wasser oder wäßrige LösungenWater or aqueous solutions
Öle, wie Triglyceride der Caprin- oder der Capryl- säure, vorzugsweise aber Rizinusöl;Oils, such as triglycerides of capric or caprylic acid, but preferably castor oil;
Fette, Wachse und andere natürliche und synthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z.B. mit Isopropanol, Propylenglykol oder Glycerin, oder Ester von Fettal¬ koholen mit Alkansäuren niedriger C-Zahl oder mit Fettsäuren;Fats, waxes and other natural and synthetic fat bodies, preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Ethanol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol , Ethylen- glykolmonoethyl- oder -monobutylether , Propylen- glykolmonomethyl , -monoethyl- oder -monobutylether, Diethylenglykol onomethyl- oder -monoethylether und analoge Produkte.Alcohols, diols or polyols of low C number, as well as their ethers, preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol onomethyl or monoethyl ether and analog products.
Insbesondere werden Gemische der vorstehend genannten Lösungsmittel verwendet. Bei alkoholischen Lösungsmitteln kann Wasser ein weiterer Bestandteil sein. Emulsionen gemäß der Erfindung z.B. in Form einer Sonnen¬ schutzcreme oder einer Sonnenschutzmilch sind bevorzugt und enthalten z.B. die genannten Fette, Öle, Wachse und anderen Fettkörper, sowie Wasser und einen Emulgator, wie er üblicherweise für einen solchen Typ der Formulierung verwendet wird.Mixtures of the abovementioned solvents are used in particular. Water can also be a component of alcoholic solvents. Emulsions according to the invention, for example in the form of a sunscreen cream or sunscreen milk, are preferred and contain, for example, the fats, oils, waxes and other fat bodies mentioned, as well as water and an emulsifier, as is customarily used for such a type of formulation.
Gele gemäß der Erfindung enthalten üblicherweise Alkohole niedriger C-Zahl, z.B. Ethanol, Isopropanol, 1,2-Propan- diol, Glycerin und Wasser bzw. ein vorstehend genanntes öl in Gegenwart eines Verdickungsmittels , das bei ölig-alko¬ holischen Gelen vorzugsweise Siliciumdioxid oder ein Aluminiumsilikat, bei wäßrig-alkoholischen oder alkoholi¬ schen Gelen vorzugweise ein Polyacrylat ist.Gels according to the invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickener, which is preferred in the case of oily-alcoholic gels, preferably silicon dioxide or an aluminum silicate, in the case of aqueous-alcoholic or alcoholic gels is a polyacrylate.
Feste Stifte gemäß der Erfindung enthalten z.B. natürliche oder synthetische Wachse, Fettalkohole oder Fettsäure¬ ester. Bevorzugt werden Lippenpflegestifte.Fixed pins according to the invention contain e.g. natural or synthetic waxes, fatty alcohols or fatty acid esters. Lip care sticks are preferred.
Als Treibmittel für erfindungsgemäße, aus Aerosolbehältern versprühbare kosmetische Desodorantien sind die üblichen bekannten leichtflüchtigen, verflüssigten Treibmittel, beispielsweise Kohlenwasserstoffe (Propan, Butan, Iso¬ butan) geeignet, die allein oder in Mischung miteinander eingesetzt werden können. Auch Druckluft ist vorteilhaft zu verwenden.Suitable blowing agents for cosmetic deodorants according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied blowing agents, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
Natürlich weiß der Fachmann, daß es an sich nichttoxische Treibgase gibt, die grundsätzlich für die vorliegende Erfindung geeignet wären, auf die aber dennoch wegen bedenklicher Wirkung auf die Umwelt oder sonstiger Be¬ gleitumstände verzichtet werden sollte, insbesondere Fluorkohlenwasserstoffe und Fluorchlorkohlenwasserstoffe (FCKW). Bevorzugt können die erfindungsgemäßen topischen Zubereitungen außerdem Substanzen enthalten, die UV-Strahlung im UVA- und/oder im UVB-Bereich absorbieren, wobei die Gesamtmenge der Filtersubstanzen z.B. 0,1 Gew.-% bis 30 Gew.- , vorzugsweise 0,5 bis 10 Gew.-! , insbe¬ sondere 1 bis 6 Gew.-% beträgt, bezogen auf das Gesamtgewicht der Zubereitungen, um kosmetische Zubereitungen zur Verfügung zu stellen, die die Haut vor dem gesamten Bereich der ultravioletten Strahlung schützen. Sie können auch als Sonnenschutzmittel dienen.Of course, the person skilled in the art knows that there are non-toxic propellant gases per se which would in principle be suitable for the present invention, but which should nevertheless be dispensed with, in particular fluorocarbons and chlorofluorocarbons (CFCs), because of their harmful effects on the environment or other associated circumstances. The topical preparations according to the invention can preferably also contain substances which absorb UV radiation in the UVA and / or in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10 wt. , in particular 1 to 6% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
Die UVB-Filter können öllöslich oder wasserlöslich sein. Als öllösliche Substanzen sind z.B. zu nennen:The UVB filters can be oil-soluble or water-soluble. As oil-soluble substances e.g. to call:
- 3-Benzylidencampher-Derivate, vorzugsweise 3-(4-Methylbenzyliden)campher, 3-Benzylidencampher ;- 3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
- 4-Aminobenzoesäure-Derivate, vorzugsweise 4-(Dimethylamino)-benzoesäure(2-ethylhexyl )ester, 4-(Dimethylamino)benzoesäureamylester ;- 4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
- Ester der Zimtsäure, vorzugsweise 4-Methoxyzimtsäure(2-ethylhexyl )ester , 4-Methoxyzi tsäureisopentylester;- Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycytic acid isopentyl ester;
- Ester der Salicylsäure, vorzugsweise Salicyls ure(2-ethylhexyl )ester, Salicylsäure(4-isopropylbenzyl)ester, Salicylsäurehomomenthylester;- esters of salicylic acid, preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester;
Derivate des Benzophenons , vorzugsweise 2-Hydroxy-4-methoxybenzophenon , 2-Hydroxy-4-methoxy-4 '-methylbenzophenon, 2,2 ' -Dihydroxy-4-methoxybenzophenon ; - Ester der Benzalmalonsäure, vorzugsweise 4-Methoxybenzalmalonsäuredi(2-ethylhexyl)ester;Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone; - Esters of benzalmalonic acid, preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester;
- 2,4,6-Trianilino-(p-carbo-2'-ethyl-1 ' -hexyloxy)-1 ,3,5- triazin.- 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1, 3,5-triazine.
Als wasserlösliche Substanzen sind z.B. zu nennen:As water-soluble substances e.g. to call:
- Salze der 2-Phenylbenzimidazol-5-sulfonsäure wie ihr Natrium-, Kalium- oder ihr Triethanolammonium-Salz, sowie die Sulfonsäure selbst;- Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself;
- Sulfonsäure-Derivate von Benzophenonen, vorzugsweise 2-Hydroxy-4-methoxybenzophenon-5-sulfonsäure und ihre Salze;- Sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
- Sulfonsäure-Derivate des 3-Benzylidencamphers, wie z.B. 4-(2-0xo-3-bornylidenmethyl)benzolsulfonsäure, 2-Methy1-5-(2-oxo-3-bornylidenmethyl)sulfonsäure und ihre Salze.- Sulfonic acid derivatives of 3-benzylidene camphor, e.g. 4- (2-0xo-3-bornylidenemethyl) benzenesulfonic acid, 2-methy1-5- (2-oxo-3-bornylidenemethyl) sulfonic acid and their salts.
Die Liste der genannten UVB-Filter, soll selbstverständ¬ lich nicht limitierend sein.The list of UVB filters mentioned should, of course, not be limiting.
Gegenstand der Erfindung sind auch erfindungsgemäße Zube¬ reitungen mit Kombinationen eines UVA-Filters mit einem UVB-Filter bzw. erfindungsgemäße kosmetische oder dermato¬ logische Zubereitungen, welche auch einen UVB-Filter enthalten.The invention also relates to preparations according to the invention with combinations of a UVA filter with a UVB filter or cosmetic or dermatological preparations according to the invention which also contain a UVB filter.
Es kann auch von Vorteil sein, die erfindungsgemäßen Wirk¬ stoffe mit UVA-Filtern zu kombinieren, die bisher übli¬ cherweise in kosmetischen Zubereitungen enthalten sind. Bei diesen Substanzen handelt es sich vorzugsweise um Derivate des Dibenzoylmethans, insbesondere um 1-(4'- tert.Butylphenyl )-3- (4 ' -methoxyphenyl )propan-1 ,3-dion und um 1-Phenyl-3- (4 ' -isopropylphenyl )propan-1 , 3-dion . Auch diese Kombinationen bzw. Zubereitungen, die diese Kombi¬ nationen enthalten, sind Gegenstand der Erfindung. Es • können die für die UVA-Kombination verwendeten Mengen eingesetzt werden.It can also be advantageous to combine the active substances according to the invention with UVA filters, which have hitherto usually been contained in cosmetic preparations. These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'- tert-Butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- (4 '-isopropylphenyl) propane-1, 3-dione. These combinations or preparations which contain these combinations are also the subject of the invention. It • The amounts used for the UVA combination can be used.
Kosmetische und dermatologische Zubereitungen gemäß der Erfindung können auch anorganische Pigmente enthalten, die üblicherweise in der Kosmetik zum Schütze der Haut vor UV-Strahlen verwendet werden. Dabei handelt es sich um Oxide des Titans, Zinks, Eisens, Zirkoniums, Siliciums, Mangans, Aluminiums, Cers und Mischungen davon, sowie Abwandlungen, bei denen die Oxide die aktiven Agentien sind. Besonders bevorzugt handelt es sich um Pigmente auf der Basis von Titandioxid. Auch diese Kombinationen von UVA-Filter und Pigment bzw. Zubereitungen, die diese Kombination enthalten, sind Gegenstand der Erfindung. Es können die für die vorstehenden Kombinationen genannten Mengen verwendet werden.Cosmetic and dermatological preparations according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide. These combinations of UVA filter and pigment or preparations containing this combination are also the subject of the invention. The amounts given for the above combinations can be used.
Alle Mengenangaben, Anteile und Prozentanteile sind, soweit nicht anders angegeben, auf das Gewicht und die Gesamtmenge bzw. auf das Gesamtgewicht der Zubereitungen bezogen .Unless otherwise stated, all quantities, parts and percentages are based on the weight and the total amount or on the total weight of the preparations.
Gegenstand der Erfindung ist auch das Verfahren zur Her¬ stellung der erfindungsgemäßen kosmetischen Mittel, das dadurch gekennzeichnet ist, daß man in an sich bekannter Weise die erfindungsgemäßen Wirkstoffe in kosmetische und dermatologische Formulierungen einarbeitet.The invention also relates to the process for the production of the cosmetic compositions according to the invention, which is characterized in that the active ingredients according to the invention are incorporated into cosmetic and dermatological formulations in a manner known per se.
Die nachfolgenden Beispiele sollen die vorliegenden Erfindung verdeutlichen, ohne sie einzuschränken. Die Zubereitungen der Beispiele zeigen hervorragende Wirkung bei der Prophylaxe und Behandlung von empfind¬ licher Haut, Photodermatosen und PLD.The following examples are intended to illustrate the present invention without restricting it. The preparations of the examples show excellent effects in the prophylaxis and treatment of sensitive skin, photodermatoses and PLD.
Die Herstellung der Zubereitungen erfolgt in an sich be¬ kannter Weise, insbesondere durch Mischen der Bestand¬ teile, gegebenenfalls bei erhöhter Temperatur. Fett und Wasserphase werden getrennt hergestellt und gegebenenfalls bei erhöhter Temperatur gemischt oder emulgiert. The preparations are prepared in a manner known per se, in particular by mixing the constituents, if appropriate at elevated temperature. Fat and water phase are produced separately and mixed or emulsified if necessary at elevated temperature.
Beispiel IExample I
Hautcreme vom W/O-TypW / O type skin cream
Fettphase: Gew.-%Fat phase:% by weight
Benzoylperoxid 5Benzoyl peroxide 5
Vaseline DAB 9 13Vaseline DAB 9 13
ParaffinölParaffin oil
(Mineralöl 5E, Shell) 26(Mineral oil 5E, Shell) 26
Cetearylalkohol/PEG-40-Cetearyl alcohol / PEG-40-
Castor Oil/Natriumcetearyl- sulfat (Emulgade F, Henkel KGaA) 2,5Castor Oil / sodium cetearyl sulfate (Emulgade F, Henkel KGaA) 2.5
Wasserphase :Water phase:
Glycerin DAB 9 6,3Glycerin DAB 9 6.3
Wasser, entmineralisiert 34,4Water, demineralized 34.4
In die 75°C warme Fettphase wird ein Gemisch aus 6,3 Gew.-% Wollwachsalkoholen und 6,5 Gew.-% Paraffinöl gegeben. Die Fettphase wird sodann zu der 75°C warmen Wasserphase gegeben, verrührt und homogenisiert, bis eine gleichmäßige weiße Creme entstanden ist.A mixture of 6.3% by weight of wool wax alcohols and 6.5% by weight of paraffin oil is added to the fat phase at 75 ° C. The fat phase is then added to the 75 ° C warm water phase, stirred and homogenized until a uniform white cream has formed.
Beispiel I hat folgende endgültige Zusammensetzung:Example I has the following final composition:
Gew.-%% By weight
Vaseline DAB 9 13Vaseline DAB 9 13
Glycerin DAB 9 6,3Glycerin DAB 9 6.3
Wasser, entmineralisiert 29,7 ParaffinölWater, demineralized 29.7 paraffin oil
(Mineralöl 5E, Shell) 37,5 Cetearylalkohol/PEG-40- Castor Oil/Natriumcetearyl- sulfat (Emulgade F, Henkel KGaA) 2,5 D(Mineral oil 5E, Shell) 37.5 cetearyl alcohol / PEG-40 Castor Oil / sodium cetearyl sulfate (Emulgade F, Henkel KGaA) 2.5 D
Wollwachsalkohole (Eucerit ) 6Wool wax alcohols (Eucerit) 6
Benzoylperoxid 5,0Benzoyl peroxide 5.0
Beispiel IIExample II
Hautcreme vom W/0-TypW / 0 type skin cream
Fettphase: G ew . . - %Fat phase: wt. . -%
Tetracyclin-HCL 3Tetracycline HCL 3
POE-GlycerolsorbitanoleostearatPOE glycerol sorbitan oleostearate
(Arlacel 581, ICI) 8(Arlacel 581, ICI) 8
Vaseline DAB 2 , , 8Vaseline DAB 2, 8
Paraffinwachs/Paraffin 1 , 8Paraffin wax / paraffin 1, 8
Ceresin 2 , , 2Ceresin 2, 2
OctyldodecanolOctyldodecanol
(Eutanol G, Henkel) 10(Eutanol G, Henkel) 10
Summe Additive (Parfüm,Total additives (perfume,
Konservierung, Stabilisation) 0,8Preservation, stabilization) 0.8
Wasserphase:Water phase:
Propylenglycol 1Propylene glycol 1
Glycerin 1Glycerin 1
Magnesiumsulfat 0,7Magnesium sulfate 0.7
Wasser, entmineralisiert 56,65Water, demineralized 56.65
Die 75°C warme Fettphase wird zu der 75°C warmen Wasser¬ phase gegeben, verrührt und homogenisiert, bis eine gleichmäßige weiße Creme entstanden ist. Bei spiel I I IThe fat phase at 75 ° C. is added to the water phase at 75 ° C., stirred and homogenized until a uniform white cream has formed. In game III
Fettphase : Gew . -Fat phase: wt. -
Salicylsäure 5Salicylic acid 5
OctyldodecanolOctyldodecanol
(Eutanol G, Henkel KGaA) 9,3(Eutanol G, Henkel KGaA) 9.3
Cetearylalkohol/PEG-40-Cetearyl alcohol / PEG-40-
Castor Oil/Natriumcetearyl- sulfat (Emulgade F, Henkel KGaA) 3,7Castor Oil / sodium cetearyl sulfate (Emulgade F, Henkel KGaA) 3.7
ParaffinölParaffin oil
(Mineralöl eE, Shell) 1,4(Mineral oil eE, Shell) 1.4
Wasserphase:Water phase:
Wasser, entmineralisiert 68,7Water, demineralized 68.7
Glycerin DAB 9 4,6Glycerin DAB 9 4.6
Die Herstellung erfolgt, wie bei Beispiel II angegeben.The preparation takes place as indicated in Example II.
Beispiel IVExample IV
HydrogelHydrogel
Benzoylperoxid 100,0 g 2-Phenylbenzimidazo1-5-sulfonsäure,Benzoyl peroxide 100.0 g 2-phenylbenzimidazo1-5-sulfonic acid,
("Eusolex 232", Merck) 27,0 g("Eusolex 232", Merck) 27.0 g
Allantoin 2,0 gAllantoin 2.0 g
Sorbit fl. ("Karion F", Merck) 22,0 gSorbitol fl. ("Karion F", Merck) 22.0 g
"Carbopol 934", B.F. Goodrich 15,0 g"Carbopol 934", B.F. Goodrich 15.0 g
Tris (hydroxymethyl)aminomethan 27,0 gTris (hydroxymethyl) aminomethane 27.0 g
Propylenglykol 10,0 gPropylene glycol 10.0 g
Ethanol 300,0 gEthanol 300.0 g
Wasser 497,0 g Parfüm, Korrigentien, Additive, Antioxidantien, Stabilisatoren nach BeliebenWater 497.0 g perfume, correctives, additives, Antioxidants, stabilizers at will
Mit den genannten Bestandteilen wird in üblicher Weise ein Hydrogel hergestellt.A hydrogel is produced in the usual way with the constituents mentioned.
Beispiel VExample V
Wäßriges Gel Gew.-%Aqueous gel% by weight
Polyacrylat,Polyacrylate,
Carbomer 5984 (B.F. Goodrich) 0,25 %Carbomer 5984 (B.F. Goodrich) 0.25%
Polyacrylat,Polyacrylate,
Carbomer 2984 (B.F. Goodrich) 0,45 %Carbomer 2984 (B.F. Goodrich) 0.45%
PEG-20-Monostearat, Myrj 49 (ICI) 2,0 %PEG-20 monostearate, Myrj 49 (ICI) 2.0%
Benzoylperoxid 5,0 %Benzoyl peroxide 5.0%
Polyethylenglycol 400 5,0 lPolyethylene glycol 400 5.0 l
Wasser ad 100 %Water ad 100%
Mit den Bestandteilen wird in üblicher Weise ein Gel hergestellt. A gel is produced with the ingredients in the usual way.

Claims

Patentansprüche Claims
1. Verwendung von Wirkstoffen oder Zubereitungen, die zur Aknebehandlung dienen oder geeignet sind, zur Prophylaxe und Behandlung von lichtempfindlicher Haut, insbesondere Photodermatosen und bevorzugt der polymorphen Lichtder¬ matose.1. Use of active ingredients or preparations which are used or suitable for acne treatment for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses and preferably polymorphic light dermatosis.
2. Verwendung gemäß Anspruch 1, dadurch gekennzeichnet, daß zusätzlich ein UV-Schutzmittel wie ein UVA-Blocker und/oder ein UVB-Blocker verwendet wird.2. Use according to claim 1, characterized in that a UV protection agent such as a UVA blocker and / or a UVB blocker is additionally used.
3. Verwendung gemäß Anspruch 1 oder 2, dadurch gekenn¬ zeichnet, daß zusätzlich ein Antioxydans oder mehrere Antioxydantien verwendet werden.3. Use according to claim 1 or 2, characterized gekenn¬ characterized in that an antioxidant or more antioxidants are additionally used.
4. Verwendung gemäß Anspruch 1, dadurch gekennzeichnet, daß Benzoylperoxid und Zubereitungen damit verwendet werden, gegebenenfalls in Kombination mit einem antibak¬ teriell wirkenden Aknemittel. 4. Use according to claim 1, characterized in that benzoyl peroxide and preparations are used therewith, optionally in combination with an antibacterial acne agent.
PCT/EP1994/000769 1993-03-15 1994-03-11 New use of anti-acne agents WO1994021241A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP6520613A JPH08507772A (en) 1993-03-15 1994-03-11 New uses for anti-acne agents
EP94911877A EP0689431A1 (en) 1993-03-15 1994-03-11 New use of anti-acne agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4307976.8 1993-03-15
DE4307976A DE4307976A1 (en) 1993-03-15 1993-03-15 New use of acne remedies

Publications (1)

Publication Number Publication Date
WO1994021241A1 true WO1994021241A1 (en) 1994-09-29

Family

ID=6482681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/000769 WO1994021241A1 (en) 1993-03-15 1994-03-11 New use of anti-acne agents

Country Status (4)

Country Link
EP (1) EP0689431A1 (en)
JP (1) JPH08507772A (en)
DE (1) DE4307976A1 (en)
WO (1) WO1994021241A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533330A1 (en) * 1995-09-11 1997-03-13 Beiersdorf Ag Anti-skin cancer topical preparations
DE19537027A1 (en) * 1995-10-05 1997-04-10 Beiersdorf Ag Skin care product for old skin

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262117B1 (en) * 1999-02-18 2001-07-17 Allergan Sales, Inc. Method and composition for treating acne
US6596209B2 (en) 2000-08-10 2003-07-22 California Agriboard Llc Production of particle board from agricultural waste
KR101352187B1 (en) * 2005-03-10 2014-02-17 제이알 켐, 엘엘씨 Stable organic peroxide compositions
MY165887A (en) * 2012-01-20 2018-05-18 Kao Corp Cosmetic composition

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021538A (en) * 1975-09-29 1977-05-03 Yu Ruey J Method for producing pigmentation in hair or skin
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
WO1982003010A1 (en) * 1981-03-04 1982-09-16 John Edward Mchugh Treatment of inflammatory viral infections,acne,dermatitis and arthritis conditions
EP0077742A1 (en) * 1981-10-20 1983-04-27 L'oreal Copper lanolate and topic compositions containing it
US4588744A (en) * 1978-09-19 1986-05-13 Mchugh John E Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
EP0232199A2 (en) * 1986-01-21 1987-08-12 Centre International De Recherches Dermatologiques Galderma - Cird Galderma Aromatic benzamido compounds, process for their preparation and their use in human or veterinary medicine as well as in cosmetics
EP0297733A2 (en) * 1987-06-03 1989-01-04 Block Drug Company, Inc. Pharmaceutical compositions comprising catecholic butanes
EP0338565A1 (en) * 1988-04-22 1989-10-25 Revlon Consumer Products Corporation N-Alkoxyalkylamides of hydroxyacids and skin treating compositions therewith
EP0421333A1 (en) * 1989-10-02 1991-04-10 Bristol-Myers Squibb Company Tretinoin emulsified cream formulations of improved stability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2096712A1 (en) * 1970-06-29 1972-02-25 Giraux Georges Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders
US4318907A (en) * 1978-04-04 1982-03-09 Westwood Pharmaceuticals, Inc. Method for treating acne vulgaris and compositions useful for that purpose
LU85111A1 (en) * 1983-12-01 1985-09-12 Oreal ANTI-ACNETIC COMPOSITION BASED ON BENZOYL PEROXIDE AND AT LEAST ONE SOLAR FILTER

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021538A (en) * 1975-09-29 1977-05-03 Yu Ruey J Method for producing pigmentation in hair or skin
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US4588744A (en) * 1978-09-19 1986-05-13 Mchugh John E Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
WO1982003010A1 (en) * 1981-03-04 1982-09-16 John Edward Mchugh Treatment of inflammatory viral infections,acne,dermatitis and arthritis conditions
EP0077742A1 (en) * 1981-10-20 1983-04-27 L'oreal Copper lanolate and topic compositions containing it
EP0232199A2 (en) * 1986-01-21 1987-08-12 Centre International De Recherches Dermatologiques Galderma - Cird Galderma Aromatic benzamido compounds, process for their preparation and their use in human or veterinary medicine as well as in cosmetics
EP0297733A2 (en) * 1987-06-03 1989-01-04 Block Drug Company, Inc. Pharmaceutical compositions comprising catecholic butanes
EP0338565A1 (en) * 1988-04-22 1989-10-25 Revlon Consumer Products Corporation N-Alkoxyalkylamides of hydroxyacids and skin treating compositions therewith
EP0421333A1 (en) * 1989-10-02 1991-04-10 Bristol-Myers Squibb Company Tretinoin emulsified cream formulations of improved stability

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Pschryrembel Klinisches Wörterbuch", 1986, WALTER DE GRUYTER, BERLIN *
J.E.F.REYNOLDS, ED.: "MARTINDALE The Extra Pharmacopoeia, 29th Ed.", 1989, THE PHARMACEUTICAL PRESS, LONDON *
O.H.MILLS ET AL.: "Acne Aestivalis", ARCH. DERMATOL., vol. 111, no. 7, July 1975 (1975-07-01), pages 891 - 892 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533330A1 (en) * 1995-09-11 1997-03-13 Beiersdorf Ag Anti-skin cancer topical preparations
DE19537027A1 (en) * 1995-10-05 1997-04-10 Beiersdorf Ag Skin care product for old skin

Also Published As

Publication number Publication date
DE4307976A1 (en) 1994-09-22
JPH08507772A (en) 1996-08-20
EP0689431A1 (en) 1996-01-03

Similar Documents

Publication Publication Date Title
EP0633017B1 (en) Cosmetic and dermatologic compositions containing delta-aminolevulinic acid
EP0656774B1 (en) Cosmetic and dermatological sunscreen compositions containing thiols and/or thiol derivates
DE4242876C2 (en) Cosmetic and / or dermatological preparations for the cosmetic and / or dermatological care of the skin and / or the skin appendages
JP2885808B2 (en) Photoprotective composition comprising tocopherol sorbate and anti-inflammatory agent
DE4420625C1 (en) Active substance combination with a content of glycerylalkyl ethers and cosmetic and dermatological preparations containing such active substance combinations
EP1194115A1 (en) Topically applied idebenone-containing agent with protective and regenerative effect
EP0688210B1 (en) Use of carnosine in combination with urocanic acid for treatment of photodermatoses
DE4444238A1 (en) Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
EP0686026B1 (en) Synergistic combinations of sunscreening substances, cosmetic and dermatological compositions containing such combinations
DE19806947A1 (en) Combination of (acyl) carnitine and (hydro)quinone for use in skin care, effective e.g. against light-induced damage and inflammation
EP0586961B1 (en) Cosmetic and dermatologic formulations containing an effective amount of cis urocanic acid
DE19615575A1 (en) Use of glucosides and ferulic acid as an anti-irritative agent in cosmetic and topical dermatological preparations
WO1994021241A1 (en) New use of anti-acne agents
EP0786246B1 (en) Cosmetic and dermatological sunscreen formulations containing triazine derivatives and polyglyceryl-2-polyhydroxystearate
DE19806946A1 (en) Combination of (acyl) carnitine and retinoid for use in skin care, effective e.g. against light-induced damage and inflammation
DE19806889A1 (en) Treatment or prevention of skin aging using acyl carnitine, effective e.g. against light-induced damage, dry skin and inflammation
DE4405585C2 (en) Use of trans-urocanic acid for the treatment or prophylaxis of oxidative stress induced skin aging
WO2002069927A1 (en) Compositions comprising melatonin and vitamin a
DE19615576A1 (en) New mono: and di:glucoside of glabridin
EP4065240A1 (en) Active substance combinations of ubichinol und hyaluronic acid and cosmetic or dermatological preparations containing said active substance combinations
DE19615574A1 (en) Use of mono and/or di:glucoside(s) of gentisin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994911877

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 522270

Date of ref document: 19950912

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1994911877

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994911877

Country of ref document: EP